These data indicate that WGP treatment expands the influence of anti-PD-1 antibody and is associated with regulating the tumor-infiltrating cells, modulating the suppressive TME, and decreasing Tregs differentiation, thus leading to a delay in tumor progression. The gene discussed is PDCD1; the disease is neoplasm.